Jan 24, 2014
Splicing Human Genome Sciences: The post-mortem on a top Md. biotech
Alongside MedImmune , Rockville-based HGS was among the most bragged-about companies in one of the state's most coveted industries.
What really happens in the aftermath of a big biotech acquisition?
Staff Reporter Bill Flook takes an in-depth look at the aftermath of the acquisition of Rockville-based Human Genome Sciences Inc. less than two years later to see what really happens after a $3 billion buyout.
Northern Michigan News
GlaxoSmithKline drug fails in late-stage study
A potential GlaxoSmithKline heart disease treatment acquired in a key company takeover fell short in a big, late-stage study.
The Washington Post
Glaxo Says Darapladib Failed to Prevent Heart Attacks in Study
GlaxoSmithKline Plc said darapladib drug for preventing plaque ruptures failed to meet the primary goal of a late-stage study of more than 15,000 patients with chronic coronary heart disease.
TUESDAY - OCTOBER 15, 2013
Dr. William Haseltine has an impressive pedigree, including Harvard Medical School, the Human Genome Sciences Inc. and the Brookings Institute.